Introduction The Irish Competition and Consumer Protection Commission (CCPC) has approved a merger under the Irish Competition Act 2002 (as amended) following the parties’ submission of a failing division argument. The transaction saw Baxter Healthcare Limited (Baxter) seeking to acquire sole control of Fannin Compounding (Fannin), its sole effective competitor in the Irish market for the manufacture and supply of aseptically prepared compounded medicines. Fannin was controlled by DCC plc, an international sales, marketing, distribution and business support services group. The CCPC’s Determination represents the first application of the so-called “failing firm” defence, as set out in section 9 of the CCPC’s Guidelines for Merger Analysis [1], since the CCPC’s approval appears to have
Share on
|
|
The Irish Competition Authority approves a merger following the parties’ submission of a failing division argument (Baxter / Fannin)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
